Kostos Louise, Rayson Victoria, Desai Jayesh, Orme Lisa, Bae Susie, Hamilton Anne, Luen Stephen J, Lewin Jeremy
Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia.
Sarcoma. 2024 Dec 13;2024:8247342. doi: 10.1155/sarc/8247342. eCollection 2024.
Prognosis remains poor for patients with relapsed or refractory Ewing sarcoma, with limited treatment options after first-line therapy. Oral etoposide has efficacy in the paediatric setting; however, data are limited in adults. A retrospective analysis was conducted on 33 patients with relapsed or refractory Ewing sarcoma who completed at least one cycle of oral etoposide at the Peter MacCallum Cancer Centre from 2005 to 2020. The median age at diagnosis and first relapse was 21 and 23 years, respectively. All patients had prior exposure to intravenous etoposide. Nine patients (27%) had stable disease for at least 6 months, and six patients (18%) had a partial response. The clinical benefit rate was 45%. The median PFS was 3.6 months (95% CI: 1.7-5.5), and OS was 8.5 months (95% CI: 4.1-13.0). Despite prior exposure, oral etoposide demonstrated antitumour activity and durable responses in the relapsed or refractory setting for adult patients with Ewing sarcoma.
复发或难治性尤因肉瘤患者的预后仍然很差，一线治疗后的治疗选择有限。口服依托泊苷在儿科患者中有效；然而，在成人中的数据有限。对2005年至2020年在彼得·麦卡勒姆癌症中心完成至少一个周期口服依托泊苷治疗的33例复发或难治性尤因肉瘤患者进行了回顾性分析。诊断和首次复发时的中位年龄分别为21岁和23岁。所有患者既往均接受过静脉注射依托泊苷治疗。9例患者（27%）疾病稳定至少6个月，6例患者（18%）部分缓解。临床获益率为45%。中位无进展生存期为3.6个月（95%CI：1.7-5.5），总生存期为8.5个月（95%CI：4.1-13.0）。尽管既往接受过治疗，但口服依托泊苷在复发或难治性成人尤因肉瘤患者中仍显示出抗肿瘤活性和持久反应。
